New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice

Hyoung Chun Kim, Chan Young Shin, Dong Ook Seo, Jin Hyeong Jhoo, Wang K. Jhoo, Won-Ki Kim, Eun J. Shin, Young H. Lee, Phil H. Lee, Kwang H. Ko

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Interest in dextromethorphan (DM) has been renewed because of its anticonvulsant and neuroprotective properties. However, DM at supra-antitussive doses can produce psychotomimetic effects in humans. Recently, we demonstrated that DM exerts psychotropic effects in mice [Neurosci. Lett. 288 (2000) 76, Life Sci. 69 (2001) 615]. We synthesized a series of compounds with a modified morphinan ring system, with the intention of developing compounds that retain the anticonvulsant activity with weak psychotropic effects [Bioorg. Med. Chem. Lett. 11 (2001) 1651]. In order to extend our understanding of the pharmacological intervention of these morphinans, we assessed their behavioral effects, and then examined whether they exert protective effects on maximal electroshock convulsions (MES) in mice. Repeated treatment (20 or 40 mg/kg, i.p./day × 7) with DM or dextrorphan (a major metabolite of DM; DX) significantly enhanced locomotor activity in a dose-related manner. This locomotor stimulation was accentuated more in the animals treated with DX, and might be comparable to that of phencyclidine (PCP). By contrast, treatment with a metabolite of DM [3-methoxymorphinan (3MM) or 3-hydroxymorphinan (3HM)], 3-allyloxy-17-methylmorphinan (CPK-5), or 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) did not significantly alter locomotor activity or patterns. The behavioral effects mediated by these morphinans and PCP paralleled the effects of conditioned place preference. DM, DX, CPK-5, and CPK-6 had anticonvulsant effects against MES, while 3MM and 3HM did not show any anticonvulsant effects. We found that DM, DX, CPK-5 and CPK-6 were high-affinity ligands at σ1 receptors, while they all had low affinity at σ2 receptors. DX had relatively higher affinity for the PCP sites than DM. By contrast, CPK-5 and CPK-6 had very low affinities for PCP sites, suggesting that PCP sites are not requisites for their anticonvulsant actions. Our results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of PCP-like behavioral side effects, and their anticonvulsant actions may be, in part, mediated via σ1 receptors.

Original languageEnglish
Pages (from-to)1883-1895
Number of pages13
JournalLife Sciences
Volume72
Issue number16
DOIs
Publication statusPublished - 2003 Mar 7
Externally publishedYes

Fingerprint

Morphinans
Dextromethorphan
Electroshock
Seizures
Anticonvulsants
Derivatives
Locomotion
Metabolites
Dextrorphan
Antitussive Agents
Phencyclidine
Animals

Keywords

  • σ receptor
  • Anticonvulsant
  • Conditioned place preference
  • Locomotor activity
  • Maximal electroshock convulsions
  • Morphinan derivatives
  • PCP receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. / Kim, Hyoung Chun; Shin, Chan Young; Seo, Dong Ook; Jhoo, Jin Hyeong; Jhoo, Wang K.; Kim, Won-Ki; Shin, Eun J.; Lee, Young H.; Lee, Phil H.; Ko, Kwang H.

In: Life Sciences, Vol. 72, No. 16, 07.03.2003, p. 1883-1895.

Research output: Contribution to journalArticle

Kim, HC, Shin, CY, Seo, DO, Jhoo, JH, Jhoo, WK, Kim, W-K, Shin, EJ, Lee, YH, Lee, PH & Ko, KH 2003, 'New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice', Life Sciences, vol. 72, no. 16, pp. 1883-1895. https://doi.org/10.1016/S0024-3205(02)02505-5
Kim, Hyoung Chun ; Shin, Chan Young ; Seo, Dong Ook ; Jhoo, Jin Hyeong ; Jhoo, Wang K. ; Kim, Won-Ki ; Shin, Eun J. ; Lee, Young H. ; Lee, Phil H. ; Ko, Kwang H. / New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. In: Life Sciences. 2003 ; Vol. 72, No. 16. pp. 1883-1895.
@article{2f90e6319efe4128aed66019f8358bc2,
title = "New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice",
abstract = "Interest in dextromethorphan (DM) has been renewed because of its anticonvulsant and neuroprotective properties. However, DM at supra-antitussive doses can produce psychotomimetic effects in humans. Recently, we demonstrated that DM exerts psychotropic effects in mice [Neurosci. Lett. 288 (2000) 76, Life Sci. 69 (2001) 615]. We synthesized a series of compounds with a modified morphinan ring system, with the intention of developing compounds that retain the anticonvulsant activity with weak psychotropic effects [Bioorg. Med. Chem. Lett. 11 (2001) 1651]. In order to extend our understanding of the pharmacological intervention of these morphinans, we assessed their behavioral effects, and then examined whether they exert protective effects on maximal electroshock convulsions (MES) in mice. Repeated treatment (20 or 40 mg/kg, i.p./day × 7) with DM or dextrorphan (a major metabolite of DM; DX) significantly enhanced locomotor activity in a dose-related manner. This locomotor stimulation was accentuated more in the animals treated with DX, and might be comparable to that of phencyclidine (PCP). By contrast, treatment with a metabolite of DM [3-methoxymorphinan (3MM) or 3-hydroxymorphinan (3HM)], 3-allyloxy-17-methylmorphinan (CPK-5), or 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) did not significantly alter locomotor activity or patterns. The behavioral effects mediated by these morphinans and PCP paralleled the effects of conditioned place preference. DM, DX, CPK-5, and CPK-6 had anticonvulsant effects against MES, while 3MM and 3HM did not show any anticonvulsant effects. We found that DM, DX, CPK-5 and CPK-6 were high-affinity ligands at σ1 receptors, while they all had low affinity at σ2 receptors. DX had relatively higher affinity for the PCP sites than DM. By contrast, CPK-5 and CPK-6 had very low affinities for PCP sites, suggesting that PCP sites are not requisites for their anticonvulsant actions. Our results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of PCP-like behavioral side effects, and their anticonvulsant actions may be, in part, mediated via σ1 receptors.",
keywords = "σ receptor, Anticonvulsant, Conditioned place preference, Locomotor activity, Maximal electroshock convulsions, Morphinan derivatives, PCP receptor",
author = "Kim, {Hyoung Chun} and Shin, {Chan Young} and Seo, {Dong Ook} and Jhoo, {Jin Hyeong} and Jhoo, {Wang K.} and Won-Ki Kim and Shin, {Eun J.} and Lee, {Young H.} and Lee, {Phil H.} and Ko, {Kwang H.}",
year = "2003",
month = "3",
day = "7",
doi = "10.1016/S0024-3205(02)02505-5",
language = "English",
volume = "72",
pages = "1883--1895",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "16",

}

TY - JOUR

T1 - New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice

AU - Kim, Hyoung Chun

AU - Shin, Chan Young

AU - Seo, Dong Ook

AU - Jhoo, Jin Hyeong

AU - Jhoo, Wang K.

AU - Kim, Won-Ki

AU - Shin, Eun J.

AU - Lee, Young H.

AU - Lee, Phil H.

AU - Ko, Kwang H.

PY - 2003/3/7

Y1 - 2003/3/7

N2 - Interest in dextromethorphan (DM) has been renewed because of its anticonvulsant and neuroprotective properties. However, DM at supra-antitussive doses can produce psychotomimetic effects in humans. Recently, we demonstrated that DM exerts psychotropic effects in mice [Neurosci. Lett. 288 (2000) 76, Life Sci. 69 (2001) 615]. We synthesized a series of compounds with a modified morphinan ring system, with the intention of developing compounds that retain the anticonvulsant activity with weak psychotropic effects [Bioorg. Med. Chem. Lett. 11 (2001) 1651]. In order to extend our understanding of the pharmacological intervention of these morphinans, we assessed their behavioral effects, and then examined whether they exert protective effects on maximal electroshock convulsions (MES) in mice. Repeated treatment (20 or 40 mg/kg, i.p./day × 7) with DM or dextrorphan (a major metabolite of DM; DX) significantly enhanced locomotor activity in a dose-related manner. This locomotor stimulation was accentuated more in the animals treated with DX, and might be comparable to that of phencyclidine (PCP). By contrast, treatment with a metabolite of DM [3-methoxymorphinan (3MM) or 3-hydroxymorphinan (3HM)], 3-allyloxy-17-methylmorphinan (CPK-5), or 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) did not significantly alter locomotor activity or patterns. The behavioral effects mediated by these morphinans and PCP paralleled the effects of conditioned place preference. DM, DX, CPK-5, and CPK-6 had anticonvulsant effects against MES, while 3MM and 3HM did not show any anticonvulsant effects. We found that DM, DX, CPK-5 and CPK-6 were high-affinity ligands at σ1 receptors, while they all had low affinity at σ2 receptors. DX had relatively higher affinity for the PCP sites than DM. By contrast, CPK-5 and CPK-6 had very low affinities for PCP sites, suggesting that PCP sites are not requisites for their anticonvulsant actions. Our results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of PCP-like behavioral side effects, and their anticonvulsant actions may be, in part, mediated via σ1 receptors.

AB - Interest in dextromethorphan (DM) has been renewed because of its anticonvulsant and neuroprotective properties. However, DM at supra-antitussive doses can produce psychotomimetic effects in humans. Recently, we demonstrated that DM exerts psychotropic effects in mice [Neurosci. Lett. 288 (2000) 76, Life Sci. 69 (2001) 615]. We synthesized a series of compounds with a modified morphinan ring system, with the intention of developing compounds that retain the anticonvulsant activity with weak psychotropic effects [Bioorg. Med. Chem. Lett. 11 (2001) 1651]. In order to extend our understanding of the pharmacological intervention of these morphinans, we assessed their behavioral effects, and then examined whether they exert protective effects on maximal electroshock convulsions (MES) in mice. Repeated treatment (20 or 40 mg/kg, i.p./day × 7) with DM or dextrorphan (a major metabolite of DM; DX) significantly enhanced locomotor activity in a dose-related manner. This locomotor stimulation was accentuated more in the animals treated with DX, and might be comparable to that of phencyclidine (PCP). By contrast, treatment with a metabolite of DM [3-methoxymorphinan (3MM) or 3-hydroxymorphinan (3HM)], 3-allyloxy-17-methylmorphinan (CPK-5), or 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) did not significantly alter locomotor activity or patterns. The behavioral effects mediated by these morphinans and PCP paralleled the effects of conditioned place preference. DM, DX, CPK-5, and CPK-6 had anticonvulsant effects against MES, while 3MM and 3HM did not show any anticonvulsant effects. We found that DM, DX, CPK-5 and CPK-6 were high-affinity ligands at σ1 receptors, while they all had low affinity at σ2 receptors. DX had relatively higher affinity for the PCP sites than DM. By contrast, CPK-5 and CPK-6 had very low affinities for PCP sites, suggesting that PCP sites are not requisites for their anticonvulsant actions. Our results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of PCP-like behavioral side effects, and their anticonvulsant actions may be, in part, mediated via σ1 receptors.

KW - σ receptor

KW - Anticonvulsant

KW - Conditioned place preference

KW - Locomotor activity

KW - Maximal electroshock convulsions

KW - Morphinan derivatives

KW - PCP receptor

UR - http://www.scopus.com/inward/record.url?scp=0037424210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037424210&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(02)02505-5

DO - 10.1016/S0024-3205(02)02505-5

M3 - Article

C2 - 12586225

AN - SCOPUS:0037424210

VL - 72

SP - 1883

EP - 1895

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 16

ER -